Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of VBI-2902a and VBI-2905a in Healthy Adults
NCT04773665Phase 1Completed
- Sponsor
- VBI Vaccines Inc.
- Start
- Mar 2021
- Primary completion
- Nov 2022
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VBI-2902 and VBI-2905 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by VBI Vaccines Inc. Primary endpoints: Rate of Local Solicited Adverse Events After Each Study Vaccination, Rate of Systemic Solicited Adverse Events After Each Study Vaccination and 1 more. Started Mar 2021; status: completed.
02
Drugs
VBI-2902VBI-2905
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04773665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04773665.